Adjunct Associate Professor, Molecular and Cell Biology, Baylor College of Medicine

Obstetrics & Gynecology

Dirk Kieback is an expert in the field of Obstetrics & Gynecology. Dirk Kieback is a published physician. He has 101 papers published. The most current publication "Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents."

Publications

---

• Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer.
• Post-cesarean adhesions--are they a unique entity?
• Society of gynecologic oncologists position paper: breast cancer care.
• Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.
• A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.
• Functional characterization of somatic point mutations of the human estrogen receptor alpha (hERalpha) in adenomyosis uteri.
• Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
• Midline intravaginal slingplasty for treatment of urinary stress incontinence: results of an independent audit up to 2 years after surgery.
• Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exe...
• Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
• Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ...
• A mutated progesterone receptor allele is more prevalent in unexplained infertility.
• Survival after relapse in patients with endometrial cancer: results from a randomized trial. C.L. Creutzberg, W.L.J. van Putten, P.C. Koper, et al., Gynecologic Oncolo...
• Expression of splicing factors in human ovarian cancer.
• Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer.
• Human vitamin D receptor mutations: identification of molecular defects in hypocalcemic vitamin D resistant rickets.
• [Central European study of the development of secondary sex characteristics in girls. I. Axillary hair as the 4th secondary sex characteristic].
• [Heart damage after electric injury].
• [Electric accidents while using electric hand tools and working with the electric equipment of processing and manufacturing machinery].
• [Awareness of safety rules of electricians--their attitude to industrial safety. Results of a standardized survey among electricians].
• [Evolution over time of fatal electrical accidents in the Federal Republic of Germany].
• [Incidence of pathologic ECG findings in survivors of electric accidents].
• [Sexual development: development of secondary sex characteristics--Tanner stages 25 years later].
• [Comparison of the Hamilton Depression Rating Scale and the Self Rating Scale BS (v. Zerssen) within a double blind study on the antidepressant effects of trazodone ve...
• Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
• Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.
• Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
• Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines.
• Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.
• Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression.
• Immunohistochemical detection of lymph node metastases in node-negative breast cancer patients.
• Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter.
• Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer.
• Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.
• Androgen receptor gene mutations do not occur in ovarian cancer.
• Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
• Comparative evaluation of seven cell collection devices for cervical smears.
• Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
• Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
• Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison.
• Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment.
• Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian...
• Molecular aspects of ovarian cancer. Is gene therapy the solution?
• Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.
• Evidence of androgen receptor expression in lichen sclerosus: an immunohistochemical study.
• A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
• Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients.
• Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin.
• The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter.
• Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy.
• Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF.
• Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer.
• Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67.
• Immunohistochemical detection of CD44 splice variant expression in premalignant lesions of the cervix and benign cervical epithelium.
• Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines.
• Identification of a meiotically expressed carbohydrate antigen in ovarian carcinoma: II. Association with proteins in tumors and peritoneal fluid.
• Identification of a meiotically expressed carbohydrate antigen in ovarian carcinoma: I. Immunohistochemical localization.
• Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
• Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy.
• Epithelial and stromal estrogen and progesterone receptor expression in endometrial cancer: true color computer-assisted image analysis versus subjective scoring.
• Chicken ovalbumin upstream promoter--transcription factor (COUP-TF) expression in human endometrial cancer cell lines.
• Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
• Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir.
• Subcellular localization of accumulated p53 in ovarian cancer cells.
• In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.
• Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen rece...
• Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL).
• Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles.
• Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines.
• p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6.
• Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian canc...
• p53 gain-of-function mutation in codon 175 is a rare event in human breast cancer.
• A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
• Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion.
• [An unusual case: vaginal foreign body (forceps) as an incidental finding during primary operation for breast cancer].
• [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
• p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer.
• Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients.
• Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis.
• Modified instruments for mobilization of the ureters and parametrial transsection during radical hysterectomy.
• [Psychological test methods in pharmacopsychiatry].
• Platelet sensitivity to a prostacyclin analogue in normal and pathological pregnancy.
• [Fetal monitoring sub partu in West Germany. I. Basic data].
• [Fetal monitoring sub partu in West Germany. III. Associations].
• [Fetal monitoring sub partu in West Germany. II. Effect of clinic size and clinic type on monitoring practice].
• [Cervix ripening using drugs before oxytocin labor induction. Clinical study of a new prostaglandin E2 triacetin gel].
• Clinical evaluation of endocervical prostaglandin E2-triacetin-gel for preinduction cervical softening in pregnant women at term.
• [Risk of thrombosis in irradiation of uterine cancer. A review with new results of studies].
• [Gestational age and birth weight. 3. Ponderal Index, fetal acid-base metabolism and hypotrophy].
• [Gestational age and birth weight. Part 2. The placenta and maternal cofactors].
• Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with fiv...
• Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
• Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5.
• Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer.
• Advanced breast cancer after subcutaneous mastectomy and immediate prosthetic reconstruction for benign breast disease--a rare observation and a diagnostic problem.
• Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets.
• [Therapy and prognosis of small breast cancers. Comparison of subcutaneous mastectomy procedures with ablatio mammae].
• [Gestational age and birth weight. 1. Intrauterine growth curves].
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-lin...
• Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer.

Doctors Specialties

---

• Gynecologic Oncology
• Obstetrics
• Gynecology

Accepted Insurances

---

Education

---

• University of Texas MD Anderson Cancer Center
• University of Kiel - Christian-Albrechts Faculty of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Lois M. Ramondetta, MD This Doctor is OpenDoctor Recommended.
	Dr. Pamela T. Soliman, MD This Doctor is OpenDoctor Recommended.
	Dr. David M. Gershenson, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Michael M. Frumovitz, MD This Doctor is OpenDoctor Recommended.
	Dr. Concepcion R. Diaz-Arrastia, MD This Doctor is OpenDoctor Recommended.
	Dr. Alex C. Vidaeff, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles F. Levenback, MD This Doctor is OpenDoctor Recommended.
	Dr. Jennifer K. Burzawa, MD This Doctor is OpenDoctor Recommended.
	Dr. Anne B. Alaniz, DO This Doctor is OpenDoctor Recommended.
	Dr. Van V. Nguyen, MD This Doctor is OpenDoctor Recommended.
	Dr. Shannon N. Westin, MD This Doctor is OpenDoctor Recommended.
	Dr. Debbie P. Spencer, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog